Glenmark settles generic tablet patent case with Janssen
Glenmark will not be able to market and distribute the generic version of Janssen's Ortho Tricyclen LO tablets
New Delhi, November 6, 2012: Glenmark Generics Inc, a subsidiary of Glenmark Pharmaceuticals today announced that the company has settled litigation with Janssen Pharmaceuticals Inc over patent actions regarding generic oral contraceptive Norgestimate and Ethinyl Estradiol tablets.
As per the settled agreements, Glenmark will now be able to market and distribute its generic tablets under a royalty bearing license from Jannsen till December 31, 2015, or earlier under certain circumstances, Glenmark Pharmaceuticals said in a statement.
The company's tablets in the strengths of 0.18/0.025 mg, 0.215/ 0.025 mg and 0.25/0.025 mg are generic version of Janssen's Ortho Tricyclen LO tablets, it added.
It is worth noting here that as per the IMS Health data, the total US sales for the tablets were nearly US$ 397 million for the twelve month period ended June 2012.